Search

Displaying results 5991 - 6000 of 10000 in total
  1. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    It is developed for the treatment of obesity and other metabolic disorders. … SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

  2. Drug

    Davunetide

    go.drugbank.com/drugs/DB12613
    Investigational

    Davunetide has been used in trials studying the treatment of Progressive Nonfluent Aphasia, Progressive Supranuclear Palsy, Predicted Tauopathies, Including, Corticobasal Degeneration Syndrome, and Frontotemporal … Davunetide is the first drug to improve memory performance by impacting the mechanisms that lead to physical damage in the brain caused by neurofibrillary tangles, one of the two established pathological

  3. Drug

    ISF402

    go.drugbank.com/drugs/DB06315
    Experimental

    ISF402 is an investigational peptide tetramer which helps dispersal of insulin via zinc chelation, therefore allowing insulin hexamers to break free.

  4. Drug

    Vamotinib

    go.drugbank.com/drugs/DB15396
    Investigational

    Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene). … Vamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With

  5. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally. … It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.

  6. Drug

    Aplaviroc

    go.drugbank.com/drugs/DB06497
    Investigational

    A spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.

  7. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  8. Drug

    Benactyzine

    go.drugbank.com/drugs/DB09023
    ApprovedWithdrawn

    Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety.

  9. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.

  10. Drug

    Parsatuzumab

    go.drugbank.com/drugs/DB14897
    Investigational

    or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)). … Parsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced